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Abstract
c-MYC controls more than 15% of genes responsible for prolifera-
tion, differentiation, and cellular metabolism in pancreatic as well
as other cancers making this transcription factor a prime target
for treating patients. The transcriptome of 55 patient-derived
xenografts show that 30% of them share an exacerbated expres-
sion profile of MYC transcriptional targets (MYC-high). This cohort
is characterized by a high level of Ki67 staining, a lower differenti-
ation state, and a shorter survival time compared to the MYC-low
subgroup. To define classifier expression signature, we selected a
group of 10 MYC target transcripts which expression is increased
in the MYC-high group and six transcripts increased in the MYC-
low group. We validated the ability of these markers panel to iden-
tify MYC-high patient-derived xenografts from both: discovery and
validation cohorts as well as primary cell cultures from the same
patients. We then showed that cells from MYC-high patients are
more sensitive to JQ1 treatment compared to MYC-low cells, in
monolayer, 3D cultured spheroids and in vivo xenografted tumors,
due to cell cycle arrest followed by apoptosis. Therefore, these
results provide new markers and potentially novel therapeutic
modalities for distinct subgroups of pancreatic tumors and may
find application to the future management of these patients
within the setting of individualized medicine clinics.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal
cancers and a major public health issue since there are approxi-
mately 230,000 new PDAC cases per year worldwide with approxi-
mately the same number of deaths (Jemal et al, 2005). Like others
malignant diseases, PDAC results from a complex combination of
genetic, epigenetic, and environmental factors which gives rise to a
particularly heterogeneous disease, with patients having different
set of symptoms, predisposition to early metastasis, and therapeutic
responses (Yachida & Iacobuzio-Donahue, 2013; Dunne & Hezel,
2015; Waddell et al, 2015). This heterogeneity highlights the neces-
sity to stratify patients with the goal of predicting better responses
to therapies (Heller et al, 2015; Koay et al, 2016; Noll et al, 2016).
One strategy to discover potential markers for patient stratification
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is to focus on identifying pathways that are deregulated in
tumors, particularly when tumor cells absolutely depend of keep-
ing these alterations (e.g., oncogene “dependence” to survive and
grow; Mancias & Kimmelman, 2011; Cohen et al, 2015). Conse-
quently, it is logical to assume that blockage of these pathways
with specific inhibitors should lead to cell growth arrest, death,
and tumor regression. Using this rational, it would be possible to
select, by means of a few markers, a particular subgroup of
patients “addicted” to a distinct pathways, a major goal of
modern individualized medicine.
A frequently deregulated, although insufficiently therapeutically
exploited pathway in PDAC involves the “dependence” to c-MYC
oncogene (Mertz et al, 2011). This transcription factor influences
the expression of a significant number of genes involved in cell
growth, proliferation, and apoptosis (Dang, 1999, 2012; Prender-
gast, 1999; Schmidt, 1999). In fact, this oncogene has been impli-
cated in the pathogenesis of one-third of all human malignancies.
As it relates to pancreatic cancer, the disease focus of the current
study, c-MYC was found to be originally amplified in more than
30% of PDAC (Schleger et al, 2002) by using interphase fluores-
cence in situ hybridization, as well as overexpressed in more than
40% of tumors (Schleger et al, 2002). However, more recently,
whole-exome sequencing of microdissected PDAC revealed that the
percentage of PDAC with amplified c-MYC gene is approximately
12% (Witkiewicz et al, 2015). Early studies confirmed the onco-
genic role of c-MYC in PDAC using genetically engineered mouse
models, which upon overexpression of this gene display increased
pancreatic tumorigenesis (Morton & Sansom, 2013). In addition,
using a variety of experimental models, it has been later shown that
upregulation of c-MYC is sufficient to induce the formation of PDAC
without additional genetic manipulation of any cell survival path-
way (Lin et al, 2013), deletion of one c-MYC allele decelerates
tumor development in vivo (Walz et al, 2014), MYC targeted by an
RNAi approach in vivo blocks PDAC development (Saborowski
et al, 2014), and the subsequent increase in PGC-1a is a key deter-
minant for the OXPHOS dependency of cancer stem cells (Sancho
et al, 2015). Interestingly, in a more recent work, Wirth and Schnei-
der propose to use c-MYC as a stratification marker of PDAC (Wirth
& Schneider, 2016). All these features indicate that c-MYC behaves
as a cancer driver gene for PDAC. Consequently, many efforts have
been dedicated to identify potent MYC inhibitors as new therapeutic
options (Soucek et al, 2008; Annibali et al, 2014; McKeown & Brad-
ner, 2014; Fletcher & Prochownik, 2015). Key to these efforts have
been the discovery that the bromodomain and extraterminal family
of proteins (BET), which are efficiently inhibited by the JQ1
compound, are necessary for c-MYC activity (Nesbit et al, 1999;
Delmore et al, 2011; Kandela et al, 2015). Notably, JQ1 suppresses
PDAC development in mice by inhibiting both c-MYC activity and
inflammatory signals (Mazur et al, 2015). Conversely, inhibition of
c-MYC expression is thought to be also an essential mechanism by
which BET inhibitors suppress tumor progression in hematological
malignancies (Knoechel et al, 2014; Roderick et al, 2014; Trabucco
et al, 2015). Thus, identifying the subgroup of pancreatic patients
based on their MYC-high status and testing their response to JQ1 is
timely and of paramount medical importance.
Several studies have focused on the discovery of predictive
markers of response to BET inhibitors. Puissant et al (2013)
reported that amplification of MYCN in medulloblastoma was the
most robust marker for predicting the sensitivity of those tumors
to JQ1. Moreover, certain rare tumors called NUT midline carci-
nomas carrying tandem fusion of BRD4 and NUT genes (nuclear
protein in testis) show an important sensitivity to BET inhibitors
(Stathis et al, 2016). However, outside to these relatively rare
examples it is very difficult to predict an efficient response to the
BET inhibitors by genomic approaches. To overcome this issue,
the use of tumoral transcriptional program can be an effective
way to develop and characterize robust predictive signatures
notably in terms of chemosensitivity.
In this work, we define a transcriptomic signature that classifies
PDAC, whose growth appears to depend on c-MYC. This result was
confirmed in a prospective validation cohort of 16 independent
PDAC. We determined that a third of patient-derived PDAC xeno-
graft bear this signature and thus were likely to respond to JQ1
treatment. Indeed, experimental therapeutic studies using matching
patient-derived cells in monolayer and 3D cultures confirm this
prediction. We conclude that having tools to determine tumors with
high c-MYC activity is of clinical interest to select patients sensitive
to BET inhibitors suggesting that a similar strategy may be useful in
the setting of individualized medicine efforts aimed at stratifying
patients to novel treatments.
Table 1. Clinicopathological parameters from the learning cohort of
patients.
Patient distribution (learning cohort)
All (%) Resectable Unresectable
n 55 30 25
Sex
Male 34 (62) 18 16
Female 21 (38) 12 9
Age
Mean 64 66 61
Min–Max 41–86 45–86 41–83
Other cancers
No 44 (80) 20 24
Yes 11 (20) 10 1
Tumor location
Head 32 (58) 19 13
Undefined 6 (11) 0 6
Body 3 (5.5) 2 1
Tail 14 (25.5) 9 5
Specimen type
Primary tumor 46 (84) 30 16
Hepatic metastasis 5 (9) 0 5
Carcinomatosis 4 (7) 0 4
Tumor status at diagnosis
Localized 29 (53) 28 1
Locally advanced 8 (14.5) 2 6
Metastasis 13 (23.5) 0 13
Carcinomatosis 5 (9) 0 5
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Results
Selection of PDAC patients with MYC-high or MYC-low activity by
using a gene expression profile signature
In order to stratify a cohort of 55 PDAC patients, 30 primary tumors
obtained from surgery and 25 biopsy samples taken by EUS-FNA
were implanted subcutaneously into mice and preserved as patient-
derived xenografts (PDX). The histopathologic and clinical charac-
teristics of patients from the learning cohort are displayed in
Table 1. The main anatomopathological characteristics of patient
primary tumors (e.g., nuclear shape and staining intensity, nucleo-
cytoplasmic ratio, eosinophilia, mucins production, and differentia-
tion degree) were preserved in xenografts after at least six
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Figure 1. Identification of a c-MYC transcriptional signature in 55 pancreatic cancer-derived xenografts.
A Hierarchical clustering and expression heatmap analyzed by a non-supervised method. MYC-high and MYC-low subgroups present different expression patterns
based on the selected 239 probe sets corresponding to MYC target genes (Hugene 2.0 ST Array, Affymetrix Genechips). MYC-high (n = 17 patients) and MYC-low
(n = 38 patients). RMA normalized gene expression is represented in color to indicate relative gene expression (high in red, low in blue).
B GSEA analysis of RMA normalized gene expression. Top score biological process significantly different between both groups (MYC-high and MYC-low) are represented;
825 gene sets from MSigDB collections were used. NES is the normalized enrichment score, and FDR corresponds to the false discovery rate.
C Ki67 expression level and differentiation degree: Samples were determined by IHC and scored from 0 to 4 for Ki67 staining (0 corresponding to negative staining and
4 to maximal staining) and from 0 to 2 for differentiation state (0 corresponding to the lowest and 2 to the maximal differentiation). Pictures representing the
different scores are provided in the Appendix. **P = 0.0018; ***P = 0.0002 (mean  SEM, n = 17 vs. 38, unpaired t-test two-tailed).
D Kaplan–Meier curves showing the overall (upper graph) and relapse-free survival (lower graph) for MYC-high and MYC-low subgroups. The P-values were calculated
using log-rank test.
Source data are available online for this figure.
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Figure 2. Determination of a set of 16 genes specific for MYC.
A Hierarchical clustering and expression heatmap for the top significantly low-expressed genes in MYC-high patients. Sixty transcripts were ranked (P = 0.01996;
Wilcoxon t-test). Data correspond to RMA normalized expression values. Red and blue colors represent relative gene expression as in Fig 1A.
B, C Box plots of the sixteen selected markers for the MYC-associated signature. In (B) are plotted the six selected transcripts that are downregulated in the MYC-high
patient group, this set was selected from the 60 transcripts indicated in (A) (P = 0.01996 and FDR ≤ 0.044). In (C) are plotted the set of 10 MYC target transcripts
upregulated in MYC-high patients which was selected from the 239 transcripts indicated in Fig 1A (P = 0.01996 and FDR ≤ 0.044).
D Box plots representing the normalized expression ratios (see Materials and Methods) for the sixteen selected transcripts in the MYC-associated signature. Ratios
were done with transcriptomic data obtained from the 55 patients used to select the MYC signature (training cohort). Ratios > 1 indicate a MYC-high profile, and
ratios < 1 correspond to MYC-low profile. § symbols indicate the four false positives detected with the signature (duplicates [2 chips/PDX]).
Data information: The line in the box-plot representation shows the median value of mRNA expression ratios; the lower and upper limits of each box represent the first
and third quartiles, respectively. Whiskers represent the limits of extreme measurements.
Source data are available online for this figure.
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successive passages (Duconseil et al, 2015). Growth rates to reach a
tumor volume of 1 cm3 ranged from 2 to 6 months in most of the
PDX. Total RNA was obtained from the 55 PDX, and gene expres-
sion profiling was performed using Affymetrix platform. Subse-
quently, we selected a panel of 239 RNAs regulated by c-MYC in
accordance with the MYC targets v1 and v2 list from Molecular
Signatures Database (MSigDB). Figure 1A represents the hierarchi-
cal clustering and heatmap for the top significantly high-expressed
genes in MYC-high patients. The dendrogram showing the genetic
distance between patients indicates the presence of two major
subgroups that we define as MYC-high and MYC-low in red and blue
colors, respectively. Interestingly, we observe that 17/55 (30.9%)
patients are characterized by an increase in the expression of
134/239 c-MYC target RNAs (P-value = 0.01996 and q-value
(FDR) = 0.044). The rank-listed transcripts are available in
Appendix Table S1. In order to gain insight into the potential biolog-
ical processes enriched in MYC-high vs. MYC-low subgroups, we
performed a Gene Set Enrichment Analysis (GSEA). As shown in
Fig 1B, the MYC-high subgroup is characterized by a low differenti-
ated phenotype and their two most significant associated biological
processes are cell cycle process (Normalized Enrichment Score = 3.60
and FDR = 0.00) and DNA replication and genome maintenance
(Normalized Enrichment Score = 3.24 and FDR = 0.00). In contrast,
the MYC-low subgroup is characterized by biological processes that
reflect a more differentiated state of pancreatic tumors such as
digestion (Normalized Enrichment Score = 2.23 and FDR = 0.00)
and glycoprotein metabolism (Normalized Enrichment Score = 1.76
and FDR = 0.00). In addition, a complete list of statistically signifi-
cant enriched signatures using Biological Process, Curated Geneset
Enriched, and Hallmarks Enriched tools is presented in Datasets EV1–
EV6. To confirm that MYC-high patients give rise to PDX with high
proliferative index, we performed an IHC-based Ki67 staining scoring
on the epithelial compartment of the 55 PDX. As shown in Fig 1C
(left part), this semi-quantitative scoring reveals that MYC-high
patient-derived PDX proliferate more than the MYC-low subgroup
(Ki67 mean score 2.88  0.25 [n = 17] vs. 2.06  0.12 [n = 38],
P = 0.0018). In addition, we determine the degree of differentiation
for both subgroups on H&E staining on paraffin-embedded tissues
sections. As shown in Fig 1C (right part), MYC-high subgroup
shows lower differentiation state than MYC-low subgroup (differen-
tiation mean score 0.77  0.2 [n = 17] vs. 1.82  0.08 [n = 38],
P = 0.0002). The Ki67 and differentiation scores are provided in
Appendix Fig S1A and B, respectively. Moreover, we analyzed the
clinical outcome of both MYC-high and MYC-low patients using a
Kaplan–Meier analysis and considering both the overall and the
relapsing free survival time for the 55 patient cohort. As shown
in Fig 1D, the overall survival median is 9.2 months for the MYC-
high vs. 18.8 months for the MYC-low subgroup (HR = 2.43 [1.1–
5.1]). The relapse-free survival median is 5.6 and 11.5 months for
MYC-high and MYC-low subgroup, respectively (HR = 2.7 [1.3–
Table 2. List of biomarkers used in the transcriptomic signature.
Gene symbol Affymetrix ID RefSeq mRNA_assignment
Upregulated transcripts
in MYC-high cohort
CDC20 16663514 NM_001255 Homo sapiens cell division cycle 20
KPNA2 16837270 NM_002266 Homo sapiens karyopherin alpha 2
PLK1 16817017 ENST00000300093 Homo sapiens polo-like kinase 1
SRM 16681611 NM_003132 Homo sapiens spermidine synthase
RFC4 16962493 NM_002916 Homo sapiens replication factor
C (activator 1) 4
MCM2 16945101 ENST00000265056 Homo sapiens minichromosome
maintenance complex component 2
RUVBL2 16863946 NM_006666 Homo sapiens RuvB-like 2 (E. coli)
MAD2L1 16979389 ENST00000296509 Homo sapiens MAD2 mitotic arrest
deficient-like 1
CCT4 16898175 NM_006430 Homo sapiens chaperonin containing
TCP1, subunit 4 (delta)
CAD 16878137 NM_004341 Homo sapiens carbamoyl-phosphate
synthetase 2
Downregulated transcripts
in MYC-high cohort
VSIG2 16745683 NM_014312 Homo sapiens V-set and immunoglobulin
domain containing 2
BCL2L15 16691121 NM_001010922 Homo sapiens BCL2-like 15 (BCL2L15)
RAB25 16671901 NM_020387 Homo sapiens RAB25, member RAS
oncogene family
TXNIP 16669796 NM_006472 Homo sapiens thioredoxin interacting
protein
CTSE 16676547 NM_001910 Homo sapiens cathepsin E, transcript
variant 1
ERN2 16825120 NM_033266 Homo sapiens endoplasmic reticulum
to nucleus signaling 2
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5.8]). Altogether, these observations indicate that we can identify
patients with MYC-high and MYC-low activity. Moreover, PDAC
with MYC-high activity is characterized by increased proliferation,
lower differentiation status and they have poor survival expec-
tancy. Combined, these observations constitute a solid characteri-
zation of the molecular, biological, and medical features of the c-
MYC status in patient-derived xenografts, which is necessary to
build the trajectory toward the testing of novel therapies aimed at
treating this distinct subgroup of tumors.
MYC-dependent RNA signatures can be used for classifying
distinct PDAC subtypes
To define a specific MYC signature that can be used to classify
tumor subtypes, we selected a total of 16 genes. The first 10
(Figs 1A and 2C) were identified from the gene set corresponding to
the upregulated genes in the MYC-high group of patients. To obtain
the genes downregulated in the MYC-high subgroup, we identified
the six top-score downregulated genes in the MYC-high patients by
a t-test analysis from the whole gene expression profiles (Fig 2A
and B). The list of these 16 markers is shown in the Table 2. For
each patient, 60 ratios were computed after mean centered normal-
ization of the 16 markers (see Materials and Methods for the
normalization method) revealing the MYC-high or MYC-low
profiles. As shown in Fig 2D, we were able to detect the 17 MYC-
high patients with medians of expression ratios up to 1 with an
excellent specificity and accuracy. Affymetrix data were then con-
firmed by RT–qPCR on four putative MYC-high and four MYC-low
patients. Each transcript was normalized to the 28S ribosomal RNA,
the relative quantity was calculated by the ΔΔCt method and the
ratios were calculated after normalization. The signature was
able to definitively detect all MYC-high and MYC-low profiles by
RT–qPCR as shown in Fig 3A and B. We then assessed the MYC
signature on primary cultures derived from the same eight
xenografts (Fig 3C) and found that the corresponding MYC-high or
MYC-low profiles were correctly detected. Therefore, we conclude
that the signature based on these transcripts is a reliable for identifying
tumor subtypes based on their c-MYC status.
We also analyzed whether or not the genetic alterations of the
c-MYC gene in PDAC tumors are predictive of the response to BET
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Figure 3. Validation of the MYC signature.
A–C Box plots representing normalized expression ratios (A) from transcriptomic data as in Fig 2D for four PDX of each group (MYC-high and MYC-low), (B) by
RT–qPCR for the same PDX as in (A), and (C) by RT–qPCR for the same eight PDX-derived primary cell cultures. The dotted line indicates the threshold 1
that differentiates between MYC-high and MYC-low profiles. The line in the box-plot representation shows the median value of mRNA expression ratios, the
lower and upper limits of each box represents the first and third quartiles, respectively. Whiskers represent the limits of extreme measurements (Mann–
Whitney t-test).
Source data are available online for this figure.
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Figure 4. MYC-high PDX were sensitive to the JQ1 compounds.
A Chemograms for eight PDX-derived cell lines. Dose–response curves after 72 h of JQ1 treatment. Cell viability is indicated in % to the control (vehicle treated). Error
bars represent SEM; n = 3.
B Box plots representing JQ1 sensitivity for the six highest concentrations used in chemograms. The line in the box-plot representation shows the median value of
mRNA expression ratios; the lower and upper limits of each box represent the first and third quartiles, respectively. Whiskers represent the limits of extreme
measurements (**P = 0.002, unpaired t-test with Welch’s correction, triplicates).
C Histograms representing IC50 for JQ1 for the four MYC-high and the four MYC-low cell lines (*P = 0.05, unpaired t-test with Welch’s correction).
D Histograms representing spheroid volumes from three derived cell lines in each group treated with 2 lM JQ1 for 72 h or with DMSO (0.05%). Data are representative
of three independent experiments made in triplicate. Phase contrast pictures were taken under a 4×/NA 0.45 lm objective lens. Black scale bars represent 100 lm
(***P = 0.0001, unpaired t-test with Welch’s correction).
E Expression of c-MYC, p27kip1 and cleaved caspase-3 of CRCM16 in primary cells treated with increasing concentrations of JQ1 or vehicle (DMSO). The graphs represent
the densitometry of each protein normalized on the b-actin levels. Densitometries were made with ImageJ software (ImageJ, National Institutes of Health, Bethesda,
Maryland, USA) (duplicates).
Source data are available online for this figure.
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inhibitors. To this end, we examined the gain (one or more alleles)
of c-MYC gene in the PDX collection. We provide the c-MYC gain
status for both MYC-high and MYC-low samples in Appendix Fig S2.
This analysis reveals that 15 of 17 PDX samples with a MYC-high
phenotype show a gain in the c-Myc gene copy number, but also 20
of 38 PDX samples from the MYC-low group. Thus, in the MYC-low
samples, which are not good responders to JQ1, approximately half
of patients also display increases in c-MYC copy number. This
phenomenon suggests that potential epigenetic mechanisms are
deployed by cells to compensate for the increase in c-MYC copy
number in this tumor. Based on this observation, we conclude that
c-MYC CNV alterations, although more frequent in MYC-high
tumors, are an unsuitable prediction method to estimate the higher
BET inhibitors sensitivity.
MYC-high PDX are sensitive to growth inhibition by the BET
inhibitor JQ1 in vitro
We hypothesized that the subgroup of PDX belonging to the MYC-
high phenotype should be more sensitives to pharmacological inhi-
bition of MYC activity, which currently cannot be targeted directly
but instead through the inactivation of BET proteins. To test our
hypothesis, we treated a panel of pancreatic PDX-derived primary
cultures with the well-characterized BET inhibitor JQ1. According to
their MYC signature, we selected four MYC-high PDX (CRCM16,
CRCM17, CRCM04, and CRCM08) and four MYC-low patients
(CRCM05, CRCM11, CRCM10, and CRCM109) (see Fig 2D). We
assessed the viability of cells with increasing dose of drug (chemo-
grams) for 72 h. As shown in Fig 4A and B, MYC-high cells exhibit
higher sensitivity to JQ1 treatment compared to the MYC-low ones.
The mean of IC50 for the MYC-high cells is 2.3 lM  0.8, whereas
the one corresponding to MYC-low primary cells was of
39.22 lM  16 (Fig 4C). We also evaluated the effect of JQ1 in
patient-derived cells grown in 3D culture conditions. As shown in
Fig 4D, MYC-high spheroids were more sensitive to the JQ1 treat-
ment for 72 h (50% reduction in volume) than their MYC-low coun-
terpart (25% reduction in volume). As a positive control, we
analyzed the effect of JQ1 treatment on the MYC-high primary cell
CRCM16 and found a significant decrease of MYC protein level
(Fig 4E). Importantly, MYC depletion is accompanied with an
increase in p27Kip1 level and an increase in the cleavage of caspase-3
which may explain the antitumor effect of the compound. Thus,
these experimental therapeutic experiments suggest that inhibition
of BET proteins by small drugs like JQ will be beneficial to antago-
nize the growth of pancreatic cells which carry the MYC-high
status.
MYC-dependent RNA signature identify MYC-high patients on an
independent validation cohort
Sixteen new PDAC patients were included in the study as an inde-
pendent validation cohort. The histopathologic and clinical charac-
teristics of patients from the test cohort are displayed in Table 3.
We obtained 16 PDX and from them six PDX-derived cells. We
measured the expression of 16 MYC-associated markers by RT–
qPCR and found that eight patients present a MYC-high profile
(CRCM43, CRCM26, CRCM50, CRCM19, CRCM30, CRCM114,
CRCM116, and CRCM34) and eight show a MYC-low profile
(CRCM23, CRCM21, CRCM108, CRCM25, CRCM28, CRCM112,
CRCM29, CRCM42) as described in Fig 5A. Of the six primary
cultures available, three presented a MYC-high (CRCM116,
CRCM114, and CRCM34) and three a MYC-low profile (CRCM112,
CRCM21, and CRCM28). To test their sensitivity to BET inhibitors,
cells were treated with increasing concentrations of JQ1 and as
expected the three MYC-high cell cultures showed to be more sensi-
tive than the MYC-low cells as shown in Fig 5B and C. The mean of
IC50 for the MYC-high cells is 5.65 lM  2.4, whereas it is
223.71 lM  191.5 for the MYC-low primary cultures (Fig 5D)
which are close to the study cohort presented in Fig 5C. These
results confirm that cells from PDAC presenting a MYC-high profile
are more sensitive to JQ1 treatment compared to the cells presenting
a MYC-low profile.
MYC-high PDX are sensitive to the BET inhibitor JQ1 in nude
mice model
Finally, we performed a preclinical analysis by treating four PDX
with MYC-high and four with MYC-low phenotypes with the JQ1
compound (50 mg/kg/day) to validate the obtained in vitro
results. As shown in Fig 6, CRCM16, CRCM04, CRCM114, and
Table 3. Clinicopathological parameters from the validation cohort of
patients.
Patient distribution (validation cohort)
All (%) Resectable Unresectable
n 16 7 9
Sex
Male 10 (62.5) 3 7
Female 6 (37.5) 4 2
Age
Mean 69 67 70
Min–Max 53–83 58–71 53–83
Other cancers
No 11 (68.75) 4 7
Yes 5 (31.25) 3 2
Tumor location
Head 5 (31.25) 3 2
Undefined 2 (12.5) 0 2
Body 2 (12.5) 1 1
Tail 7 (43.75) 3 4
Specimen type
Primary tumor 13 (81.25) 7 6
Hepatic metastasis 2 (12.5) 0 2
Carcinomatosis 1 (6.25) 0 1
Tumor status at diagnosis
Localized 7 (43.75) 7 0
Locally advanced 1 (6.25) 0 1
Metastasis 6 (37.5) 0 6
Carcinomatosis 2 (12.5) 0 2
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CRCM116 (MYC-high) samples efficiently responded to treat-
ment. On the contrary, samples with the MYC-low phenotype
(CRCM05, CRCM10, CRCM109, and CRCM112) were more resis-
tant. Altogether, from the in vitro and in vivo results, we can
assume that MYC-high tumors are more sensitive to the BET
inhibitors.
Discussion
Current treatments for patients with a PDAC are not highly effective
primarily due to the recently discovered fact that these tumors are
both molecularly and clinically heterogeneous. For example, the
response of these tumors to gemcitabine and Folfirinox, the two
A B
C D
p=0.0398 p=0.05
Figure 5. Verification in a validation cohort.
A Box plots representing normalized expression ratios for the MYC signature in 16 new PDX used as validation or test cohort. The line in the box-plot representation
shows the median value of mRNA expression ratios; the lower and upper limits of each box represent the first and third quartiles, respectively. Whiskers represent the
limits of extreme measurements. qPCR in duplicate for each PDX.
B Chemograms for eight PDX-derived cell lines with MYC-high (red) or MYC-low (blue) profiles were subjected to JQ1 treatment as in Fig 4A. Cell viability is indicated
as % of the control (vehicle treated). Error bars represent SEM; n = 3.
C Graph representing JQ1 sensitivity for the six highest concentrations used in chemograms. Horizontal lines represent the median  SEM (*P = 0.014; **P = 0.0398,
Welch’s t-test).
D Histograms representing IC50 for JQ1 for the three MYC-high and the three MYC-low cell lines taken from the validation cohort (mean  SEM, unpaired t-test with
Welch’s correction).
Source data are available online for this figure.
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gold standard therapies against PDAC, is only 10% (Burris et al,
1997) and 31% (Conroy et al, 2011), respectively. The variability in
this response seems to be due, on one hand, to the difficulty for the
drugs to reach the transformed cells because of the compact PDAC
stroma (resulting in hypovascularization) and, on the other hand, to
the marked differences in cellular susceptibility to drugs into the
tumors due to their molecular heterogeneity. Therefore, it has
become important to develop methods to stratify patients in a
manner that allows predicting their susceptibility to the treatments
so as to increase their therapeutic responses which will result
in increased survival expectancies. Consequently, in this work, we
focused our attention on a subgroup of PDAC, which are
characterized by a deregulation of the c-MYC pathway, established a
molecular signature that allows us to identify those tumors of the
MYC-high subtype and showed that they are highly sensitive to BET
inhibitors. Based on this observation, we conclude that the develop-
ment of tools to determine tumors with high deregulation in the c-
MYC pathway is of clinical interest to select patients sensitive to
BET inhibitors, a goal that can help with the design and administra-
tion of individualized medicine protocols.
The oncogene c-MYC is the “corner stone” of several proliferative
pathways involved in PDAC development such as RAS-RAF-MEK-ERK
and PI3K-AKT pathways that stabilize c-MYC by preventing its
degradation by the proteasome (Sears et al, 2000; Dai et al, 2006;
Zhu et al, 2008). Consistent with these observations, we chose to
define c-MYC transcriptional program as a restricted signature that
allowed the selection of distinct subtype of PDAC tumors. This
MYC-associated signature was established by using selected c-MYC
target genes available from the molecular signature database and
who are reported to be directly regulated by this transcription factor
(MYC target v1 and v2 from MsigDB). From the 239 putative c-
MYC-dependent genes, 16 targets were selected according to the fold
change between MYC-high and MYC-low PDAC. Those targets
usefully identify highly proliferative PDAC with low degree of dif-
ferentiation and patients with poor clinical outcome as shown in
Fig 1C and D. An efficient signature, like the one reported here,
which is easily applicable and low cost, for detecting patients
having a MYC-high PDAC is of clear clinical interest, particularly
in non-operable patients which represent about 85% of PDAC.
Currently, in these patients, a biopsy is systematically taken by
EUS-FNA before starting the antitumor treatment as a diagnosis
confirmation procedure. These biopsies represent a valuable
source of cancer cells which may serve as the source of tumor
RNA. In turn, this RNA may be used for measuring the expression
of a set of RNAs of interest. We envision that in the near future
treatments of cancer patients will be preceded by the molecular
characterization of their tumor in order to select the more appro-
priate treatments toward an individualized medicine approach.
PDAC is undoubtedly one of the malignant diseases that most
urgently need this type of approaches since the treatment with
standard available drugs are almost inefficient. Conceptually,
targeting on the pathways, which are dominantly deregulated such
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Figure 6. JQ1 is a more potent inhibitor in MYC-high PDX in vivo.
Four PDX with MYC-high (CRCM16, CRCM04, CRCM114, and CRCM116) and four with MYC-low (CRCM05, CRCM10, CRCM109, and CRCM112) phenotypes were treated with
50 mg/kg/day of JQ1 or with vehicle for 28 days by i.p. injections (n = 3 per group). ***P < 0.001, **P < 0.01 and *P < 0.05 in two-way ANOVA with Bonferroni post-test
(mean  SEM).
Source data are available online for this figure.
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as those driven by oncogenes such as Kras and c-MYC by specific
drugs, could be of major interest for patients and we presume that
it may have repercussions in terms of survival. This work was
focused on c-MYC, but a similar approach can be applied to other
pathways for PDAC as well as for other cancer types. Our work
was also benefited by the existence of well-characterized drugs
that reliably inhibit the c-MYC pathway such as JQ1, a thienotria-
zolodiazepine, and a potent inhibitor of the BET family of
proteins which includes BRD2, BRD3, BRD4, and BRDT (Filip-
pakopoulos et al, 2010; Asangani et al, 2014). Mechanistically,
JQ1 competitively inhibits the BET proteins from binding to
acetylated lysine residues of histones (Jung et al, 2014; Korb
et al, 2015). This process prevents the association of transcrip-
tional complexes with chromatin and thus decreases expression
of RNA species that are dependent of this mechanism of tran-
scription (Smith & Zhou, 2016). Many studies suggest that the
main mechanism by which BET inhibitors affect tumoral growth
is by their effects on c-MYC expression and activity (Knoechel
et al, 2014; Roderick et al, 2014; Trabucco et al, 2015). However,
a recent paper suggests an additional antitumor effect of JQ1 on
PDAC via the inhibition of CDC25B, a regulator of cell cycle
progression. Whether this effect is specific to JQ1 or common to
BET inhibitors remains to be demonstrated (Garcia et al, 2016).
Lastly, in hepatocellular carcinoma, MYC expression does not
seem to be predictive of the response of these tumors to JQ1
(Huang et al, 2014). Therefore, we can assume that MYC level is
not indicative of the MYC activity or, alternatively, that
the response to JQ1 could be specific in certain tissues, although
testing both of these hypotheses remains the topic of future
investigations.
In conclusion, this study is the first to report a strategy, which
begun by molecularly characterizing patient-derived PDX as well as
to define a molecular signature that can help to select PDAC patients
with deregulation in the c-MYC pathway and showing that these
tumors are more sensitive to the BET inhibitor treatment. We
presume that a therapeutic strategy against PDAC by using BET
inhibitors, in combination with standard anticancer drugs, could be
a promising strategy in well-selected patients. A similar approach
can be applied to other pathways for PDAC or other cancer types,
highlighting its potential to contribute to the development of novel
individualized therapies for malignant diseases, which currently
remain incurable.
Materials and Methods
Ethics statements
The study was performed according to the principles set out in the
WMA Declaration of Helsinki and to the protocols approved by the
Department of Health and Human Services Belmont Report. Patients
were included in this project under the Paoli Calmettes Institute clin-
ical trial NCT01692873 (https://clinicaltrials.gov/show/NCT01692873).
Three expert clinical centers collaborated on this project after receiving
ethics review board approval. Patient informed consent forms were
collected and registered in a central database.
For animal studies, all mice, housed under specific pathogen-
free conditions, were 4-week-old males on a Swiss nude
background (Crl: Nu(lco)-Foxn1nu, Charles River, Wilmington,
MA). Mice were used at 6 weeks of age, and all animal studies
were approved by the Animal Facility and Experimental Platform
(Scientific and Technological Park of Luminy, Marseille, France)
and the French Ministry of National Education and Research under
the reference number: 02859.01. All animal experiments were
conducted in accordance with the Guides for the Use and Care of
Laboratory Animals (ARRIVE guidelines). The animal house is run
by professional employees fully equipped with state-of-the-art
instrumentation in order to maintain the standard of animal
welfare at the maximum levels. All mice were housed in individ-
ual, ventilated cages (IVCs) with 12-h light/dark cycles with food
and water ad libitum.
PDAC samples and cell culture
Two types of samples were obtained: endoscopic ultrasound-guided
fine-needle aspiration (EUS-FNA) biopsies from patients with
unresectable tumors and tumor tissue samples from patients under-
going surgery. All the samples were anonymized, and postsurgical
anatomopathology reports were provided. Histopathologic evalua-
tion was performed on 5-lm hematoxylin and eosin stained sections
of patient tumors and xenografts and examined under a light micro-
scope. These sections were compared with the original human
tumor when available. Samples from EUS-FNA were mixed with
100 ll of MatrigelTM (BD Biosciences, Franklin Lakes, NJ) and
injected in the upper right flank of a nude mouse (Swiss Nude
Mouse Crl: NU(lco)-Foxn1nu; Charles River Laboratories, Wilming-
ton, MA). Samples from surgery were fragmented, mixed with
100 ll of MatrigelTM, and implanted with a trocar (10 gauge; Innova-
tive Research of America, Sarasota, FL) in the subcutaneous right
upper flank of an anesthetized and disinfected mouse. When the
tumors reached 1 cm3, the mice were sacrificed, and the tumors
were removed. Xenografts that failed to develop within 6 months
were discontinued. The study on animals was approved by the
Animal Facility and Experimental Platform (Scientific and Techno-
logical Park of Luminy, Marseille, France).
Primary cell cultures were obtained from xenografts. Tissues
were split into several small pieces and processed in a biosafety
chamber. After a fine mincing, they were treated with collagenase
type V (ref C9263; Sigma) and trypsin/EDTA (ref 25200-056; Gibco,
Life Technologies) and suspended in DMEM supplemented with 1%
w/w penicillin/streptomycin (Gibco, Life Technologies) and 10%
fetal bovine serum (Lonza). After centrifugation, cells were re-
suspended in Serum Free Ductal Media (SFDM) adapted from
Schreiber et al (2004) without antibiotic and incubated at 37°C in a
5% CO2 incubator.
Gene expression microarrays
Total RNA was purified from xenograft using TRIzol Reagent
(Gibco, Life Technologies) according to the manufacturer. Briefly,
50–100 mg of fresh frozen tissue per ml of TRIzol was disrupted
using a homogenizer followed by a single step of phenol/chloro-
form purification. Total RNA was quantified using the Nanodrop
spectrophotometer (NanoDrop Technologies, Inc), and RNA Integ-
rity Number (RIN) was calculated using the Agilent 2100 Bioana-
lyzer (Agilent Technologies, Santa Clara, CA). RNA samples that
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reached a RIN between 8 and 10 were used for microarray
hybridization (GeneChip; Affymetrix Inc., Santa Clara, CA). The
Genechip Human Gene 2.0 ST Arrays were washed and stained
using the Affymetrix GeneChip fluidic station 450 (protocol
EukGE-WS2v5_450) and were scanned using a GeneChip scanner
3000G7 (Affymetrix Inc., Santa Clara, CA). GeneChip operating
software version 1.4 (Affymetrix Inc., Santa Clara, CA) was used
to obtain chip images and for quality control. Background subtrac-
tion and normalization of probe set intensities were performed
using the method of Robust Multi-array Analysis (RMA; Irizarry
et al, 2003). Microarray analysis was performed by the CHU de
Que´bec Research Center Gene Expression Platform (Quebec City,
Quebec, Canada). Seventeen samples of the cohort were previ-
ously published (Duconseil et al, 2015) as GEO accession numbers
GSE55513 and GSE89792.
Bioinformatics analysis
Robust Multi-array Analysis normalized data from microarrays were
imported into GENE-E (version 3.0.204; Broad Institute, Cambridge,
MA, USA) to generate heatmaps. The color intensity on the heatmap
reflects global expression within a minimum (25%) in blue and a
maximum (75%) in red. Cluster analysis, using Euclidean distance
correlation of samples only, and distance for the clustering were
calculated using a complete linkage algorithm. Differentially
expressed genes were identified using t-test ratio, and false discov-
ery rate was estimated using Benjamini & Hochberg method
(Benjamini et al, 2001). Gene set enrichment analysis (GSEA) was
performed using the Broad Institute platform, and statistical signifi-
cance (false discovery rate) was seated at 0.05.
GSEA analysis
Two categories of pre-defined gene sets in the Molecular Signatures
Database (MSigDB, Broad Institute, Cambridge, MA, USA) were
selected for analysis named the Hallmarks set, and the C5 set, a
Gene Ontology (GO) molecular function gene set derived from the
Molecular Function Ontology database (Subramanian et al, 2005).
The gene sets included in the analysis were limited to those that
contained between 15 and 500 genes. Permutation was conducted
1,000 times according to default-weighted enrichment statistics and
by using a t-test ratio metric to rank genes according to their dif-
ferential expression levels across the MYC-high and MYC-low
groups. Significant gene sets were defined as those with a nominal
P < 0.05. Calculation of the false discovery rate (FDR) was used to
correct for multiple comparisons and gene set sizes (Benjamini et al,
2001).
SNP arrays analysis
DNA was extracted for 55 PDX samples using the Blood & Cell
culture DNA mini kit (Qiagen) following the manufacturer’s instruc-
tions. Illumina Infinium HumanCode-24 BeadChip SNP arrays were
used to analyze the DNA samples. Integragen SA (Evry, France)
carried out hybridization, according to the manufacturer’s recom-
mendations. The BeadStudio software (Illumina) was used to
normalize raw fluorescent signals and to obtain log R ratio (LRR)
and B allele frequency (BAF) values. Asymmetry in BAF signals
due to bias between the two dyes used in Illumina assays was
corrected using the tQN normalization procedure (Staaf et al,
2008). We used the circular binary segmentation algorithm (Venka-
traman & Olshen, 2007) to segment genomic profiles and assign
corresponding smoothed values of log R ratio and B allele
frequency. The Genome Alteration Print (GAP) method was used to
determine the ploidy of each sample, the level of contamination
with normal cells, and the allele-specific copy number of each
segment (Popova et al, 2009). Chromosomal instability index (CIN)
was estimated by the mean number of SNP probes with a loss or
gained status normalized by chromosomes length. SNP data are
available through ArrayExpress (http://www.ebi.ac.uk/arrayexpre
ss) under accession E-MTAB-5006.
Chemograms
Cells were screened for their chemosensitivity to JQ1 compound
(Sigma-Aldrich, St Louis, MO, USA). Five thousand cells per well
were plated in 96-well plates in SFDM medium. Twenty-four
hours later, the media was supplemented with increasing concen-
trations of JQ1 and incubated for an additional 72-h period. Each
experiment was done in triplicate and repeated at least three
times. Ten increasing concentrations of JQ1 were used ranging
from 0 to 30 lM.
Spheroids outgrowth assay
Fifteen thousand cells per well were seeded in 96-well round bottom
plates with medium containing 20% methylcellulose (Sigma-
Aldrich, St Louis, MO, USA). After 48-h incubation, cells with spher-
oids of uniform size and shape were incubated with 2 lM JQ1
during 72 h. Images were captured every day with an Evos micro-
scope, equipped with a 4×/N.A. (0.13) objective lens (Thermo
Fisher Scientifics, Waltham, MA, USA). Spheroids volumes were
determined by the following equation: Vspheroids = 4/3 p*r
3. Results
were expressed as a percentage of spheroid growth compared with
no treatment condition (DMSO 0.05%).
Viability assays
Cell viability was estimated after addition of PrestoBlueTM reagent
(Life Technologies, Carlsbad, CA, USA) for 3 h, following the
supplier protocol. For spheroid viability assays, the viability was
estimated after addition of CellTiter-Glo 3D for 1 h, following the
supplier protocol (Promega, Madison, USA).
Proteins extraction and Western blotting
Cells were washed with ice-cold PBS and lysed in Laemmli sodium
dodecyl sulfate-sample buffer (90 mM Tris–HCl [pH 6.8], 2.5%
sodium dodecyl sulfate, 15% glycerol). Samples were then boiled
and sonicated, and protein concentrations were determined using
the bicinchoninic acid (BCA) assay (Bio-Rad, Hercules, CA, USA)
with bovine serum albumin as standard. b-mercaptoethanol and
bromophenol blue were then added to a final concentration of 1%
and 0.005%, respectively. Proteins (20 lg) were separated by SDS–
PAGE in 10% or 12.5% gels and were detected immunologically
following electro-transfer onto equilibrated PVDF (Imobilon-P
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membranes, Millipore, Billerica, MA, USA). PVDF membranes were
stained with Ponceau Red to assure a correct transfer of proteins
and molecular weight markers. Membranes were blocked in PBS
containing 5% powdered milk and 0.05% Tween-20 for 1 h at 25°C.
Membranes were then incubated overnight at 4°C with primary anti-
bodies in blocking solution and thereafter with horseradish peroxi-
dase-conjugated IgG for 1 h. Blots were visualized using the
Amersham ECL system. The c-MYC antibody was purified from
hybridomas clone 9E10 and used at 1/500 (ATCC CRL-1729, ATCC
France). The p27kip1 antibody (C19) was purchased from Santa Cruz
and used at 1/1,000. The cleaved caspase-3 (Asp175) antibodies
was purchased from Cell Signaling (#9661) and used at 1/500. The
b-actin antibody (AC-74) was purchased from Sigma-Aldrich and
used at 1/10,000.
Real-time quantitative PCR
Total RNA (1 lg) was used as a template for cDNA synthesis, using
the GoScriptTM reverse transcription kit (Promega, Madison, WI,
USA). The GoTaq qPCR 2X Master Mix (Promega, Madison, WI,
USA) that include all components for quantitative PCR, except
sample DNA, primers and water, was used to quantify the sixteen
MYC-high signature markers. Primer lists for each transcript are
available in Appendix Table S2. Reaction conditions were denatura-
tion at 95°C for 2 min; 40 cycles of 15 s at 95°C, 45 s at 60°C. Reac-
tions were carried out using the AriaMx real-time PCR system and
analyzed using the AriaMx software v1.1 (Agilent Technologies,
Santa Clara, CA, USA).
Ki67 staining and quantification
Full-thickness, 5-lm sections were cut from formalin-fixed, paraf-
fin-embedded blocks from all 55 PDX. The samples were then
stained with the Ki67 antibody (MIB-1 clone, 1:160; Dako, France)
using tonsillar tissue as a positive control. Negative controls were
run simultaneously with the primary antibody replaced with a
buffer. Antigen retrieval was conducted in citrate buffer at pH 6.0
under pressure for 3 min. Envision Dual Link Kit (Dako) was used
for detection, with diaminobenzidine (DAB) as the chromogen and
hematoxylin as the counterstain. Staining was considered positive
when brown nuclear labeling was observed in epithelial compart-
ment. A standard Olympus BX41 microscope (Olympus Corp.,
Tokyo, Japan) was used to identify tumor hot spots in each case.
The percentage of tumor cell staining was independently counted
by three reviewers (BB, MB, and ND) and with “eyeballing”
methodology.
Differentiation scoring
Formalin-fixed tumors were submitted to the Hoˆpital Nord histol-
ogy core facility, and paraffin-embedded sections were cut for
hematoxylin and eosin (H&E) staining. For histopathologic scor-
ing, H&E-stained slides were scored for the penetrance of each
histological hallmark on a scale of 0–2. The predominant tumor
phenotype gave the pathological score for the whole tumor
(0 = poorly differentiated, 1 = moderately differentiated, 2 = well
differentiated).
Method for normalizing expression ratios
Considering the expression of upregulated gene i in patient a as uia
and the expression of downregulated gene j in patient a as dja. We
calculate the sum of expression of each marker in all patients:
Ui ¼
X
a
uia; 1\i\10 and Dj ¼
X
a
dja; 1\i\6
The mean centered normalized expression was then calculated
for the two set of markers:
fUia ¼ Uiað100Þ
Ui
and fDja ¼ Djað100Þ
Dj
The normalized ratio between upregulated gene Ui and downreg-
ulated gene Dj is:
frija ¼ fUiafDja
 !
; 1\i\10 and 1\j\6
The median of the 60 normalized ratios is then calculated:
fma ¼ median ðfrija ; 81\i\10 and 1\j\6Þ
fma[ 1 show a MYC-high profile and fma\1 show a MYC-low
profile.
Treatment with JQ1 of PDX with MYC-high and MYC-low
phenotype in vivo
We transplanted four PDX samples with the MYC-high phenotype
(CRCM16, CRCM04, CRCM114, and CRCM116) and four with the
MYC-low phenotype (CRCM05, CRCM10, CRCM109, and
CRCM112) subcutaneously into 6-week-old male Swiss nude mice
(Crl: Nu(lco)-Foxn1nu, Charles River, Wilmington, MA). Each
PDX sample was inoculated into six nude NMRI mice who were
randomized for treatment (n = 3) and vehicle (n = 3). When the
PDX reached 100 mm3, we started the treatment with JQ1
or vehicle and followed their growth for 28 days. JQ1 was
prepared according to published procedures (Filippakopoulos
et al, 2010) and administered intraperitoneally every day at
50 mg/kg. Tumor size was measured with a Vernier caliper
twice weekly, and the tumor volume was calculated with the
equation v = (length/width2)/2.
Statistical analysis
Overall survival and relapse-free survival were analyzed using the
Kaplan–Meier log-rank test to assess differences in survival. Box-
and-whisker plots show the medians, quartiles, and range of
continuous data to demonstrate the variability of data and the
degree of normality. For continuous variables, non-parametric
unpaired two-tailed t-test was performed under the assumption of
equal variance.
Expanded View for this article is available online.
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